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Polycystic ovary syndrome (PCOS) is one of the most common 
endocrine disorders with an estimated prevalence of 7% to14% among 
reproductive-aged women. Although the exact underlying etiology of 
PCOS is not entirely clear, however, evidence has shown that insulin 
resistance, hyperandrogenemia and adipose tissue dysregulation play key 
roles on its pathogenesis. The syndrome is recognized as a cardio-
metabolic disorder. Data have shown that traditional cardiovascular and 
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metabolic risk factors including hypertension, dyslipidemia, metabolic 
syndrome, obesity and central obesity, glucose intolerance and diabetes are 
more prevalent among PCOS patients. In addition, subclinical 
cardiovascular markers such as coronary artery calcium scores, C-reactive 
protein, carotid intima-media thickness and endothelial dysfunction are 
more likely to be increased in women with PCOS. Nevertheless, there is 
much more controversy regarding whether cardio-metabolic events are 
increased in PCOS in later life, leaving many issues regarding 
cardiovascular and metabolic events unresolved. This chapter will discuss 
the literature on PCOS and cardio-metabolic risk factors and provides 
recommendations that would be helpful for healthcare provider and policy 
makers in the monitoring and management of these risk factors in PCOS 
population. Treatment options are beyond the scope of this chapter. 
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Polycystic ovary syndrome (PCOS) is the most common endocrine 
disorder, with an estimated prevalence of 7% to 20% among women of 
reproductive age [1-3]. Heterogeneous by nature, the syndrome is 
characterized by a combination of signs and symptoms of ovarian 
dysfunction (including oligo/anovulation, and/or polycystic ovarian 
morphology (PCOM)) and androgen excess (including hyperandrogenemia 
and/or hyperandrogenism), after the exclusion of other related disorders [4, 
5]. 
The exact underlying etiology and pathogenesis of PCOS remains 
largely unknown, but it seems to be a complex interactions between 
multifactorial components of genetic, epigenetic, environmental and 
lifestyle factors [6, 7]. The imbalance in sex hormones and insulin resistance 
(IR) are considered to be a main factor of the reproductive and metabolic 
abnormalities in PCOS [8, 9]. Insulin resistance with compensatory 
increased insulin production contributes to hyperandro-genemia due to the 
augmentation of ovarian androgen production and the inhibition of hepatic 
sex hormone-binding globulin secretion [5]. Moreover, PCOS is closely 
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linked to adipose tissue dysregulation [10], which is characterized by 
hypertrophic adipocytes and impairments in lipolysis and insulin action [11, 
12]. Further, chronic low grade inflammation [13, 14] and excessive 
formation of oxidative stress [15, 16] have been actively implicated in the 
etiology of the syndrome. 
Data have shown that traditional cardiovascular/metabolic risk factors 
such as obesity and central obesity [17, 18], increased carotid intima media 
thickness [19, 20] and coronary artery calcifications [21] are more common 
among women with PCOS compared with the age-matched women without 
the syndrome.  
However, despite the presence of cardiovascular risk factors and 
increased surrogate markers of cardiovascular disease, it is not clearly 
understood whether PCOS patients have accelerated atherosclerosis or other 
cardiovascular events and also greater mortality, the latter mainly because 
of a lack of long term endpoint studies.  
This chapter addresses, summarizes, and discusses salient data from the 
existing literature, including gaps and uncertainties, aspects, and 
mechanisms related to the spectrum of adverse cardiometabolic profile 
factors in women with PCOS. 
This chapter outlines, summarizes, and discusses salient data from the 
existing literature, including gaps and uncertainties, latest advances and 
current limitations and mechanisms related to the spectrum of 
cardiometabolic aspects in PCOS.  
 
 
1.1. Definition of PCOS 
 
Some sets of criteria for diagnosis have been proposed for PCOS. At the 
first time, National Institutes of Health (NIH) in 1990 introduce the PCOS 
diagnosis criteria including only presence of clinical and/or biochemical 
hyperandrogenism and oligo/anovulation [22]. Later, two international 
consensus have developed adult diagnostic criteria that broaden the 
definition beyond NIH criteria by incorporating the presence of polycystic 
ovary morphology [23, 24] as a diagnostic criterion for PCOS. Rotterdam 
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criteria in 2003 are the broadest and encompass all combinations and require 
two of three features including oligo/anovulation, clinical and/or 
biochemical hyperandrogenism and PCOM in ultrasound assessment [25]. 
Androgen Excess-PCOS (AE-PCOS) Society criteria in 2006 encompass 
otherwise unexplained hyperandrogenism with either oligo/anovulation or 
PCOM [23].  
In addition, the presentation of PCOS reflects at least four possible 
phenotypes (Phenotypes A–D) depending on the presence or absence of 
three general features of oligo-anovulation, androgen excess and polycystic 
ovarian morphology) [26] 
 
• Phenotype A: Hirsutism/hyperandrogenemia + Ovulatory 
dysfunction + Polycystic ovaries (classic combination of all the 
reproductive endocrine features) 
• Phenotype B: Hirsutism/hyperandrogenemia + Ovulatory 
dysfunction  
• Phenotype C: Hirsutism/hyperandrogenemia + Polycystic ovaries  
• Phenotype D: Ovulatory dysfunction + Polycystic ovaries 
 
Whether these phenotypes represent a continuum of the same condition, 
but PCOS phenotypes with hyperandrogenism and oligo/ anovulation had 
the worst metabolic presentations in terms of insulin resistance, diabetes, 
obesity, metabolic syndrome and cardiovascular disease [27-29]. However, 
further characterization of PCOS phenotypic differences is an important area 
for ongoing research. 
The diagnosis of PCOS in adolescent female populations is 
complicating, since adolescence is a transitional stage of physical and 
psychological development and functional variations in the hypothalamic-
pituitary-ovarian axis during normal puberty leads to changes in 
reproductive hormones and menstrual patterns that mimic some of the 
features of PCOS. Moreover, many of the PCOS features may evolve over 
time and change during the first few years after menarche. There is no 
consensus on precise diagnosis of PCOS in adolescents [30] Therefore, 
international consensus have endorsed more stringent criteria including 
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using all three components of the Rotterdam criteria [31] or using NIH 
criteria for diagnosis of PCOS in adolescents [32]. However, precise 
definition of PCOS in adolescent is essential, since associated 
cardiometabolic morbidity such as obesity, insulin resistance and 
dyslipidemia may benefit from early intervention approaches. 
 
 
1.2. Pathogenesis of Polycystic Ovary Syndrome 
 
PCOS is a multifactorial disease. The interaction between genetic 
predisposition, intra-uterine (prenatal) and postnatal environmental factors 
may comprise in development of PCOS [6, 7, 33].  
Although, the genes that are involved in the etiology of the syndrome 
have not been fully understood yet, the role of genetic factors in PCOS is 
strongly supported [34-38]. Studies of twins in which women with 
monozygotic twin sisters affected by PCOS and also first-degree relatives of 
women with PCOS were shown to have higher the risk of developing PCOS 
features and metabolic disturbances, which suggests a genetic background 
effect and familial condition. Although there are low external validity, gene 
variants of lots of coding genes associated with the clinical and laboratory 
features of PCOS have been demonstrated in these populations [39]. In 
addition, some genes have shown altered expression indicating that the 
genetic abnormality in PCOS affects signal transduction pathways 
regulating insulin, gonadotrophin and steroid hormones action and 
production as well as energy homeostasis, chronic inflammation and others 
[40]. 
In addition, environmental factors potentially could involve in PCOS 
development which are classified as prenatal intra-uterine developmental 
programming and postnatal factors [41-43]. Evidence suggests that 
environmental stimuli can both mimic hormonal actions and activate pre-
existing, predisposing factors that trigger the endocrine activity 
characteristic of PCOS [6]. Glucocorticoids excess during critical period of 
fetal development, either by the fetal origin (resulting from fetal hypoxia and 
IUGR) [44, 45] or maternal source (resulting from elevation of endogenous 
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or exogenous maternal androgen levels during pregnancy) [46, 47] may 
related to PCOS developmental programming. It may lead to functional 
changes in organs, endocrine pathways and subsequently clinical, metabolic 
and reproductive changes during postnatal life [48]. In this respect, it is 
demonstrated that sexual function of women whose mothers also had PCOS 
and therefore potentially may had prenatal androgen exposure, was 
significantly decreased compared to women whose mothers did not [49]. In 
addition, postnatal factors including diet and nutrition, obesity, sedentary 
lifestyle, environmental toxins, medications and social and economic factors 
may play a role in development of PCOS [42].  
 
 
1.3. PCOS and Traditional Cardio-Metabolic Risk Factors 
 
1.3.1. Insulin Resistance, Glucose Intolerance and Diabetes Mellitus 
Insulin resistance play a key role in the metabolic manifestations among 
women with PCOS which is independent of BMI and obesity [50]. The 
prevalence of IR among women with PCOS is estimated around 30% and 
70%, based on the women’s age, obesity status and ethnicity [51]. In this 
respect, older age, higher BMI and Hispanic ethnicity exacerbates IR to a 
greater extent in women with than those without PCOS, irrespective of the 
definition used [8, 50, 52]. However, it is well documented that high 
testosterone and low sex hormone-binding globulin (SHBG) concentrations 
are independently associated with IR [53-55]. It has been shown that the 
PCOS phenotypes with hyperandrogenism are strongly associated with 
insulin resistant, irrespective of BMI or central adiposity [9, 56, 57]. 
Additionally, it seems that despite common genetic variations at the diabetes 
related loci in PCOS and non PCOS women, the association between IR and 
diabetogenic polymorphisms may be affected by PCOS status [58]  
There are several underlying mechanisms have been proposed for the 
development of IR in PCOS including (i) an increase in serine 
phosphorylation that causes post-binding defects in insulin signalling [59], 
and disturbances in the tyrosine phosphorylation of insulin receptors and 
insulin receptor substrate-1 that affects metabolic pathways in classic insulin 
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targets mainly adipocytes, skeletal muscles and ovaries [59], (ii) reduced 
insulin receptor-β abundance in omental adipose tissue, reduced glucose 
transporter 4 (GLUT4) in subcutaneous adipocytes, both leading to 
reduction in glucose uptake, (iii) reduced hepatic clearance of insulin, (iv) 
mitochondrial dysfunction, constitutive activation of serine kinases in the 
mitogen-activated protein kinase/extracellular signal-regulated kinases 
pathway [59], (v) genetic disruption of insulin signalling in the central 
nervous system (vi) chronic low-grade inflammation with increased tumor 
necrosis factor-alpha (TNF-α) secretion from mononuclear cells [60, 61] 
(vii) increased iron tissue depots due to chronic oligo/anovulation that lead 
to impair insulin secretion by oxidative damage of β cells and decrease 
insulin clearance and muscle glucose uptake [62, 63]. However, increased 
level of insulin due to the both increased insulin production and reduced 
insulin clearance in liver, could induce higher androgen secretion. 
Hyperandrogenemia per se could change insulin action in the target tissues 
leading to increase visceral adiposity in PCOS women [64].  
It should be noted that IR and hyperinsulinemia may play further 
important roles in the modulation of cardiovascular risk. Insulin resistance 
may lead to disturbance in natriuretic peptides (NP) which are secreted from 
cardiomyocytes and directly influence blood pressure, body fluid 
homeostasis, and various metabolic functions including lipolytic activity 
[65, 66]. Insulin increases the expression of NP clearance receptor in adipose 
tissue, independent of glycemia [67-69].  
Although there is some variability in reports of the prevalence of 
prediabetes and DM among women with PCOS, most studies agree that 
women with PCOS have a higher prevalence of impaired fasting glucose 
(IFG), impaired glucose tolerance (IGT), and DM, especially among the 
obese. [3, 70-73]. In a prospective study of 254 PCOS women, it is showed 
that that 31% of PCOS patients had impaired glucose intolerance, and 7.5% 
had diabetes; a 3- to 7-fold higher than the age-comparable population, and 
around a 2-fold higher risk compared with age- and BMI-comparable 
women with normal cycles [74]. In another long term population based 
prospective study among 178 women with PCOS and 1524 eumenorrheic, 
non-hirsute, healthy women, it is showed that the risk of developing diabetes 
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and prediabetes in young women with PCOS is 4.9 and 1.7 times higher, 
respectively, than in the general female population after adjustment for 
potential related confounders. In contrast, those hazard differences between 
PCOS and controls disappeared in their late reproductive years [70]. A 
recent systematic review and meta-analysis of 40 quality studies found 
women with PCOS had an increased prevalence of impaired glucose 
tolerance (IGT) (OR = 3.26, 95% CI: 2.17-4.90) and T2DM (OR = 2.87, 
95% CI: 1.44-5.72), which differed by ethnicity (for IGT, Asia: 5-fold, the 
Americas: 4-fold and Europe: 3-fold), was higher with obesity [73].  
Taken together, the findings support close monitoring, with screening 
for T2DM in women with PCOS [75]. In this respect, the Endocrine Society 
[32] and ESHRE/ASRM [25] recommended the use of OGTT in all 
adolescents and adult women with PCOS. Nevertheless, there is no evidence 
on the optimal time for serial screening, but it has been arbitrarily suggested 
every three to five years, except for an earlier worsening in clinical 
symptomatology [32]. Reciprocally, the European Society of Endocrinology 
(ESE) in 2014 endorsed an oral glucose tolerance test (OGTT) in all obese 
and lean women with PCOS older than 40 years, with a positive history of 
GDM or family history of T2DM [76].  
 
1.3.2. Dyslipidemia 
There are many studies showed that dyslipidemia is one of the common 
feature of metabolic disturbances among women with PCOS [59, 77]. A 
meta-analysis in 2011 reported that PCOS patients had 26.39 (95% CI 17.24, 
35.54) mg/dl higher TG levels, 6.41 (95% CI 3.69, 9.14) mg/dl lower HDL-
C and 18.82 (95% CI 15.53, 22.11) mg/dl higher non- HDL-C levels 
compared with age matched controls. LDL-C levels were also higher even 
in studies with BMI matching [8.32 mg/dl, 95% CI (5.82,10.81] [78].  
The exact underlying mechanisms that involved to developing 
dyslipidemia in PCOS are not clearly described, but it has been hypothesized 
that the intertwined effects of obesity, insulin resistance and 
hyperandrogenism induce dyslipidemia among women with PCOS [79-81].  
The mechanisms by which obesity is associated with dyslipidemia in 
women with PCOS include insulin resistance, overproduction of VLDL, 
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abnormal lipoprotein lipase-mediated lipolysis and a defect in the insulin-
signaling pathway mediated by an overexpression of PI3KR1 gene [81]. 
Androgens decrease catabolic removal of LDL by attenuating estrogen 
receptor-mediated induction of LDL receptor activity and also upregulate of 
genes responsible for catabolism of HDL [81, 82]. In addition, IR leads to 
hepatic overproduction of apolipoprotein B-containing VLDL and 
hypertriglyceridemia [81, 82]. In particular, IR increases the production of 
VLDL, decreases the elimination of VLDL and chilomicrons from the 
circulation and increases the clearance of apolipoprotein A, the major 
component of HDL-C [83, 84].  
Those lipid metabolic dysfunction in women with PCOS definitely 
exaggerates the risk for cardiovascular disease (CVD) with aging [79]. 
Although various patterns of dyslipidemia have been described, the most 
common profile mong women with PCOS is generally characterized by 
increased serum concentration of low density lipoprotein cholesterol (LDL-
C) and very-low density lipoprotein cholesterol (VLDL-C), triglyceride 
(TG) and free fatty acid, as well as decreased serum level of high density 
lipoprotein cholesterol (HDL-C), particularly HDL2-C, due to reduced 
apolipoprotein A-I (apoA-I) [59, 85] and higher level of oxidized LDL-C, 
independent of BMI, [86]. However, this atherogenic profile is exacerbated 
by increased BMI and IR. However, the lipoprotein profile in PCOS is 
therefore similar to that seen in T2DM patients [51]. Therefore, it is worth 
noting that lipid pattern in women with PCOS is only modestly more 
atherogenic compared with healthy women with similar BMI [51].  
However, there are some concerns that most of those available evidence 
usually derived from clinical-based studies with small sample sizes, lacked 
appropriate control groups, used heterogeneous diagnostic criteria, and did 
not adjust potential confounders. Moreover, clinical-based studies might be 
misleading; they present severe phenotypes of PCOS women referred for 
treatment. On the other hand, a population-based study might include 
younger, lower BMI women with less severe phenotypes that might have 
never been referred.  
However, long-term population-based cohort study, did not confirmed 
the higher risk of dyslipidemia compared to general population [4]. 
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However, population based studies with larger sample sizes and long term 




There are some evidence showed that blood pressure, particularly 
systolic blood pressure may increase in PCOS patients [51]. In this respect, 
Obesity and insulin resistance are considered key factors for the alteration 
of blood pressure in women with PCOS [87]. Insulin resistance and 
compensatory hyperinsulinemia in PCOS leads to an imbalance in the 
autonomic nervous system, increased renal sodium reabsorption, as well as 
a reduction in the production of nitric oxide [88, 89]. As well, it could 
interfere with the endothelium-dependent vasodilatation mechanisms 
causing vascular muscle wall hypertrophy [90, 91]. Obesity and central 
obesity as most prevalent feature in PCOS, lead to metabolic, endothelial 
and vascular dysfunction, neuroendocrine imbalances, sodium retention, 
glomerular hyperfiltration, proteinuria, and maladaptive immune and 
inflammatory responses; all associated with hypertension [92] among 
women with PCOS. Endothelial dysfunction is a major forerunner of 
obesity-related hypertension by impairing control of the vascular tone and 
by promoting structural changes of the vessel wall [61, 93]. Furthermore, 
renin-angiotensin system activation [94] due to hyperandrogenism and 
endothelial dysfunction due to increased endothelin-1 levels in women with 
PCOS regardless of BMI [87, 95] may play a role in developing of 
hypertension in the syndrome.  
However, the studies addressing the prevalence of HTN in PCOS had 
conflicting results. Observational studies reported that the prevalence of 
hypertension, mainly systolic blood pressure in PCOS women is estimated 
at 9–25.7%, higher than the general population [96-99]. However, other 
cohort studies did not confirm a higher incidence of hypertension [4, 100]. 
A results of meta-analysis confirmed a greater risk of HTN in PCOS patients 
but demonstrates that this risk is increased only in reproductive age women 
with PCOS, indicating that after menopause, having a history of PCOS may 
not be as an important predisposing factor for developing HTN [101].  
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In conclusion, evidence about whether or not rates of hypertension 
increase differently over time in women with PCOS is inconclusive. There 
might be a predisposition of these women to hypertension in later life that 
may set the milieu for potential accelerated progression of cardiovascular 
events irrespective of BMI and centripetal obesity [102], the assumption 
need to be further clarified.  
 
1.3.4. Obesity 
Obesity is a key contributor to the clinical and metabolic manifestations 
of PCOS patients. However, there is little debate about the association 
between obesity, especially central obesity, and cardiovascular risk factors. 
Several methods are used to assess the content and distribution of body fat. 
BMI assessment is commonly used for evaluation of obesity and prediction 
of adverse cardio-metabolic outcomes as strong predictor for IR and 
metabolic syndrome [103]. Recently some metabolic parameters of lipids 
were added to adiposity indices for better prognostic evaluation of cardio-
metabolic adverse events. However, less is known regarding the complex 
adiposity indexes, in women with PCOS. However, there are some studies 
showed that lipid accumulation product (LAP) [104], visceral adiposity 
index (VAI) [105] and a body shape index (ABSI) [103] were a good tool 
for assessing cardiometabolic risk in among PCOS patients.  
In this respect, it is well recognized that a large proportion of women 
with PCOS are suffering from overweight, obesity and central obesity 
compared with age-matched controls [8, 18, 51, 103]. In a meta-analysis, 
women with PCOS had two fold higher risk of overweight (RR: 1.95; 95% 
CI:1.52, 2.50), three fold higher risk of obesity (RR: 2.77; 95% CI: 1.88, 
4.10) and two fold central obesity (RR:1.73; 95% CI: 1.31, 2.30) compared 
to healthy women [106]. Although, magnetic resonance imaging (MRI) in 
women with PCOS and health controls matched for BMI and fat mass 
showed no difference in body fat distribution [107, 108], however, increased 
waist to hip ratio affects between 50-70% of those patients, independent to 
BMI [10, 109].  
In general, Adipose tissue in PCOS is characterized by aberrant 
cellularity, which probably alters adipose tissue function and most likely 
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contributes to metabolic disturbances in women with the syndrome. 
Adipocyte size reflects the balance between triglyceride storage and 
mobilization [110]. Overweight or obesity in PCOS may be attributable to 
IR, which leads to hyperinsulinemia that stimulates ovarian steroidogenesis 
and subsequent reduction in sex hormone-binding globulin (SHBG) [111]. 
Obesity could also increase the androgens, particularly total testosterone and 
free androgen index that can lead to the accumulation of visceral fat causing 
central obesity [80, 112]. In addition, obesity through obesity-related 
haemodynamic and metabolic abnormalities, leads to increased circulating 
blood volume, systemic vascular resistance, and activation of SNS and the 
renin-angiotensin system, that could potentially increase the risk of 
hypertension and CVD [113, 114]. Moreover, visceral obesity is associated 
with low-grade inflammation and raised inflammatory cytokines and 
proinflammatory factors such as TNF-α, interleukin-6 (IL-6) and 
interleukin-18 (IL-18), which are secreted by activated tissue marcophages 
infiltrated in adipose tissue, both of which are associated with CVD in 
patients with PCOS [115-117]. However, all of those alteration are related 
to metabolic and reproductive disturbances in PCOS patients and strongly 
influences the severity of its clinical, cardiometabolic, and endocrine 
disturbances in these women. 
 
1.3.5. Adipokines 
PCOS is closely associated with adipose tissue dysfunction [11]. 
Androgen excess, as experienced by women with PCOS, is often associated 
with adipocyte hypertrophy and both adipose tissue hypertrophy and 
hyperandrogenism are strongly associated with IR [11]. As well, Chronic 
low-grade inflammation in PCOS is also associated with androgen excess 
and to the hypertrophy of adipocytes, leading to adipose tissue dysfunction 
and altered secretion of cytokines [118]. 
Adipose tissue is an active endocrine organ and release a large number 
of bioactive peptides, involving in the regulation of energy homeostasis, 
reproduction, insulin action, lipid metabolism and systemic inflammation 
[119] that is generally called adipokines. Emerging evidence suggest that 
abnormal production, release or function of adipokines are one of the 
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important underlying potential mechanisms associated with the increased 
risk of cardio-metabolic risk factors and IR in PCOS [11, 120-122]. The two 
main important and well-known of adipokines are adiponectin and leptin.  
Adiponectin, as an anti-inflammatory cytokine, is exclusively produced 
by adipose tissue and plays a role in a variety of functions including the anti-
inflammatory, anti-atherogenic mediator, and insulin-sensitizing effects 
[123]. This peptide, is adversely associated with the adipocyte mass and 
visceral adiposity [124, 125]. There are some evidence reporting that the 
serum level of adiponectin was significantly decreased in disorders with IR 
including obesity, metabolic syndrome, diabetes, and obesity-related 
cardiovascular diseases [123, 126-128].  
In a meta-analysis, it is showed that women with PCOS had significantly 
lower adiponectin level compared to healthy counterparts regardless of the 
degree of obesity [123]. Obesity, as a prevalent manifestation of PCOS, can 
downregulate adiponectin through alterations in the expression of 
adiponectin receptors and reduces the adiponectin sensitivity. It leads to 
insulin resistance that in turn aggravates hyperinsulinemia in women with 
PCOS [129]. In addition, some adiponectin gene polymorphism is more 
expressed in PCOS, which may be related to the reduced secretion of 
adiponectin [130].  
In contrast to adiponectin, leptin has a central and peripheral regulatory 
role in energy expenditure regulation, based on to the levels of energy stored 
as body fat [131]. As such, insulin indirectly regulates the secretion of leptin 
through its trophic effect on adipocytes by stimulates leptin gene expression 
[132, 133]. Leptin may also contribute to increased level of androgens by 
inducing steroidogenesis and inhibiting neuropeptide Y, which leads to 
increasing serum level of gonadotropin releasing hormone (GnRH) and 
lutenizing hormone (LH) [59, 134]. Moreover, increased serum level of 
leptin is associated  with systemic inflammation, IR and high risk of 
atherosclerosis [135, 136]. In a meta-analysis involving 991 women with 
PCOS and 898 controls, it is revealed the higher leptin concentration in 
patients with PCOS compared to healthy women (standardized mean 
difference: 1.62, 95% CI: 1.01-2.23) and obesity exacerbated the increased 
level of leptin in PCOS patients [137].  
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However, the profile of most adipokines in PCOS is not still understood 
and the studies focusing the role on other adipokines are insufficient and 
controversial. However, exact underlying physiological and 
pathophysiological function of adipokines in the regulation of obesity and 
PCOS needs to study the dynamic interaction between adipokines and other 
potential pathways. In this respect, some adipokines such as adiponectin, 
leptin, omentin, resistin, irisin, apelin, vaspin, and visfatin are more 
dependent on obesity and insulin pathways [10, 11, 131, 133, 138-143] and 
some such as chemerin are more involved in low-grade inflammatory 
responses [141, 144], even some may participate in both pathways.  
However, there is a long way a head to understand the role of adipokines 
in PCOS, which may act as a link between obesity and PCOS. 
 
1.3.6. Metabolic Syndrome 
Metabolic syndrome (MetS) is a cluster of endocrinopathy and 
metabolic disturbances including hyperglycemia/insulin resistance, central 
obesity, dyslipidemia and hypertension [145]. Among women, it is 
diagnosed by the presence of any three of the following criteria including (i) 
increased waist circumference of ≥90 cm, (ii) increased triglycerides of ≥150 
mg/dL, (iii) decreased HDL-C of < 50 mg/dL, (iv) increased blood pressure 
including ≥130 mmHg for systolic and/or ≥85 mmHg for diastolic and (v) 
increased fasting glucose ≥100 mg/dL [146].  
Women with PCOS potentially have an elevated risk of the individual 
components of MetS including dyslipidemia, hyperglycemia and 
hypertension [147-149]. These patients also have increased novel and 
nontraditional cardiovascular risk factors including elevated carotid intima 
media wall thickness and coronary artery calcification, increased 
inflammatory cytokines, endothelial dysfunction, arterial stiffness, carotid 
or aortic plaque [21, 111, 150-153]. It is suggested that IR in PCOS plays a 
major role in the pathway of potential pathological mechanisms responsible 
for the development of MetS in women with PCOS [111, 154, 155]. The 
potential underlying of clinical manifestations of MetS is debated in this 
chapter.  
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However, the results of studies about the risk of MetS in PCOS is 
controversial. In a meta-analysis, women with PCOS had a higher 
prevalence of MetS (OR 3.35, 95% CI 2.44, 4.59), particularly in overweight 
or obese PCOS patients (OR 1.88, 95% 1.16, 3.04) but not in lean women 
(OR 1.45, 95% CI 0.35, 6.12) [111]. In contrast, in another recent meta-
analysis, the odds of MetS had no differences between adults with PCOS 
compared to healthy controls in population-based studies. These results were 
confirmed by the subgroup meta- analysis of some studies using age and 
BMI adjustment/matching [156], indicating that age, BMI and study design 
can affect the risk of MetS in PCOS.  
 
 
1.4. PCOS and Non-Traditional Cardio-Metabolic Risk Factors 
 
1.4.1. Hyperandrogenism and Severe PCOS Phenotypes 
It is well documented that androgen excess as the most prominent 
feature in PCOS, per se, is also correlated with CVD in female [157]. 
Hyperandrogenism is closely associated with aggravation of central obesity, 
IR, atherogenic lipid profile including lowering HDL-C and increasing 
LDL-C [158, 159] which are the metabolic core for the development of 
CVD. Although obesity may play a role, but it is demonstrated that 
testosterone could increase angiotensinogen and renin gene expression 
which contribute to hypertension [160-162]. Moreover, it have been found 
to increase the appetite [163], chronic inflammation, and oxidative stress 
associated with PCOS [164-166]and also involve in anxious and depressed 
mood states [167, 168]. Along with metabolic effects, androgens directly 
have adverse effect on vasculature, promoting endothelial dysfunction [169-
172] and accelerating atherosclerotic alterations [20, 173].  
Women with severe phenotypes PCOS, mainly phenotype A and B who 
have, seems to have a more adverse cardio-metabolic profile, particularly 
increased prevalence of glucose intolerance and metabolic syndrome and 
also worse lipid profile with higher LDL and non-HDL cholesterols 
compared to milder phenotypes [78, 158, 174, 175]. However, it appear to 
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be generally related to androgen excess, adiposity and central adiposity in 
those subPCOS population [158].  
 
1.4.2. Chronic Inflammation  
Evidence in support of the presence of chronic low-grade systemic 
inflammation a as a key contributor to the underlying pathogenesis of PCOS 
is incontrovertible. There is a genetic basis for the inflammation reported in 
PCOS [176]. It is demonstrated that women with PCOS have decreased anti-
inflammatory agents, such as adiponectin and omentin [105], and increased 
proinflammatory cytokines such as C-reactive protein (CRP), TNF-α [177-
179], interleukin-18, monocyte chemoattractant protein-1, oxidative stress 
and white blood count are increasing in women with PCOS [13, 179-181], 
independent of obesity and BMI, consistent with a chronic low-grade 
inflammatory state. However, chronic inflammation is strongly associated 
with development, progression, and prognosis of endothelial dysfunction 
and CV events in PCOS patients [179, 182]. As such, Inflammation is also 
likely to be associated with other prominent aspects of PCOS including 
insulin resistance and hyperandrogenism [180, 183]. However, further 
studies required to clear the role of inflammation in developing CVD in 
PCOS. 
 
1.4.3. Oxidative Stress 
Oxidants are chemical products that tend to gain electrons losing 
positive charge. They include products of normal cellular metabolism 
including reactive oxygen species (ROS) and reactive nitrogen species that 
derive from nitric oxide (RNS). ROS derive from molecular oxygen, and 
include oxygen ions, free radicals (chemical species with unpaired electrons) 
and peroxides [184]. Oxidative stress is characterized by as the imbalance 
between production and scavenging of oxidants and antioxidants [185]. 
Oxidants excess leads to DNA, cellular lipids and proteins damage, and 
could disturb their physiological function. Therefore, oxidative stress may 
involves in many underlying pathophysiology of human pathologic situation 
as well as in the physiologic process of ageing [186]. 
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Emerging evidence revealed that oxidative circulating markers are 
significantly increased in patients with PCOS compared to healthy women 
[187]. In this respect, homocysteine, asymmetric dimethylarginine, and 
malondialdehyde as a promoters and by-products of oxidative stress are 
increased in women with PCOS, contrary, glutathione and paraoxonase-1 as 
antioxidants are decreased in women with PCOS independent of age and 
BMI [184, 188] which may shows that oxidative stress play an important 
role in pathophysiology of PCOS.  
Obesity, androgen excess, insulin resistance and dyslipidemia in PCOS 
could induce inflammatory response oxidative stress by increased ROS-
related oxidative stress, muscle activity to carry excessive weight, 
hyperleptinemia, chronic inflammation and inadequate antioxidant defences 
in PCOS, [189] even in the absence of excess adiposity [190)]. Circulating 
and molecular markers of oxidative stress and inflammation are also highly 
correlated with circulating androgens [116, 117]. Nevertheless, the effect of 
the abnormalities in oxidative stress is relatively small, and their clinical 
significance as cardiovascular risk factors needs to be precisely defined in 
future. 
 
1.4.4. Haemostasis and Fibrinolysis Imbalance 
There is no doubt that haemostatic system abnormalities could increase 
arterial and venous thromboembolism as important cardiovascular risk 
factors [191]. However, there is relatively strong literature suggesting that 
PCOS is associated with increased platelet aggregation and impaired plasma 
fibrinolytic activity with increased plasminogen activator inhibitor-1 and 
plasminogen [192, 193]. Those risks are exacerbated by oral contraceptive 
use, as a common PCOS treatment strategy [194]. Although those 
abnormalities are likely to increase cardiovascular disease in PCOS 
population, however further studies are warranted.  
 
1.4.5. Vitamin D Deficiency 
Vitamin D is a fat-soluble vitamin that is synthesized endogenously by 
sunlight-stimulated photochemical conversion of cholesterol to 7-
dehydrocholesterol in the skin or obtained from the diet [195]. Vitamin D is 
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known for its primary role in bone and mineral homeostasis. However recent 
evidence demonstrates its vitamin D deficiency contributes in a spectrum of 
pathologic process of metabolic disturbances and CVD [196]. Evidence has 
demonstrated that vitamin D receptor complex regulates genes contributed 
in glucose and lipid metabolism and also in blood pressure regulation, 
thereby indicating a role of vitamin D deficiency in the underlying 
pathogenesis of cardiovascular disease [197]. In this respect, vitamin D 
deficiency increases both insulin resistance and activation of 
proinflammatory process leading to glucose intolerance by β-cell damage 
and death. Moreover, it may activate the epigenetic alterations by 
hypermethylation in many diabetes-related genes as a feature of diabetes 
[198, 199]. It is showed that vitamin D deficiency has a negative effect on 
lipid profile particularly on total cholesterol and LDL cholesterol, 
apolipoprotein AI and HDL cholesterol levels [200, 201]. Moreover, 
Calcitriol is a pro-inflammatory and anti-inflammatory cellular cytokines 
modulator [202]. There is some evidence that vitamin D deficiency is 
negatively correlated with inflammatory markers such as CRP 
concentrations [203]. As well, Vitamin D also imply a crucial role in the 
modulation of innate and adaptive immune response in various 
inflammatory and autoimmune disorders. It is now recognized that active 
metabolite vitamin D receptors are expressed in cells of the immune system 
[204, 205].  
However, vitamin D regulates about 3% of the human genome, 
including genes that are crucial for glucose and lipid metabolism, via its 
nucleoprotein receptor that binds to vitamin D response elements found in 
the promoter region of responsive genes [206]. 
However, studies showed that vitamin D deficiency are so prevalent 
among women with PCOS and it may play a key role in the development of 
PCOS [207, 208]. The genetic variant of the VDR was found to have an 
association with severity of clinical features of PCOS, but none with disease 
risk [206]. As well a recent meta-analysis showed that lower serum vitamin 
D levels were related to metabolic and hormonal disorders in women with 
PCOS, particularly dysglycemia including increased levels of fasting 
glucose and insulin resistance compared to those without vitamin D 
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deficiency [209, 210]. However, result of studies focusing on the effect of 
vitamin D supplementation on metabolic and endocrine parameters in PCOS 
in insufficient and inconclusive. Therefore, given the heterogeneity of the 
current available studies, a definite conclusion is difficult to make. Well-
designed randomized controlled trials are still needed to clarify the effect 




1.5. PCOS and Cardiovascular Events 
 
There is much more controversy regarding whether the risk of 
cardiovascular events are increased among women with PCOS [211, 212]. 
However, increased cardiovascular risk factors in PCOS is translated into 
increased risk for cardiovascular events remains to be established, 
considering that PCOS may improve with aging. In this respect, some 
studies have shown that hyperinsulinemia and hyperandrogenemia are 
independently associated with the presence of atherosclerosis and 
cardiovascular events [159, 213]. However, most probably, PCOS 
phenomenon and therefore the attributed cardiovascular risks in women with 
PCOS progressively normalizes with aging. It has been reported that the 
progressive reduction of ovarian and adrenal androgen secretion in the 
decade preceding menopause reduces the risk factors [214].  
In agreement with this hypothesis, a recent published metanalysis 
evaluated the prevalence and hazard ratio of cardiovascular events among 
reproductive and menopausal women with PCOS, compared to healthy 
controls. However, 16 studies were included for final meta-analysis. Results 
showed that the pooled hazard of CV events in PCOS patients in both 
subgroups of reproductive and menopausal age were significantly 1.5 fold 
higher than healthy controls. However, sub group analysis among studies 
with population-based design, which may show the general PCOS 
population characteristics, revealed that the HR of CV events increased only 
in reproductive age PCOS patients, whereas the difference was not 
statistically significant when comparing menopausal PCOS patients to 
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healthy controls [215]. It may suggested that history of PCOS during 
reproductive ages may not be a great risk factor for developing 
cardiovascular events in later life. At present, well designed, long term 
population based prospective studies, initiated in the reproductive period, 





PCOS is a common heterogeneous endocrinopathy among reproductive-
aged women with significant adverse health impacts. Both traditional and 
non-traditional cardiometabolic risk factors may interact in PCOS, 
contributing to increased cardiometabolic risks, which are further 
exacerbated by high rates of concomitant obesity. Nevertheless, there is 
much more controversy regarding whether cardio-metabolic disease are 
increased in PCOS in later life, leaving many issues regarding 
cardiovascular and metabolic events unresolved. Overall, at present 
methodological heterogenicity, failure to control of confounders and also 
absence of long term follow up of PCOS population have hampered progress 
in understanding cardiometabolic aspects in PCOS. Larger-scale studies that 
address these gaps are needed to better characterize mechanisms and 
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